BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Translational Research 2014;163:533-56. [DOI: 10.1016/j.trsl.2014.01.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP, Chaparro M. Ustekinumab to treat Crohn's disease. Gastroenterol Hepatol 2017;40:688-98. [PMID: 29042094 DOI: 10.1016/j.gastrohep.2017.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
2 Taks M, Pijls PA, Derijks LJ, Ten Broeke R, Grouls RJ, Curvers J, Gilissen LP. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2017;29:169-73. [PMID: 27749780 DOI: 10.1097/MEG.0000000000000763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS One 2019;14:e0225572. [PMID: 31800627 DOI: 10.1371/journal.pone.0225572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
4 Ream JM, Doshi A, Lala SV, Kim S, Rusinek H, Chandarana H. High Spatiotemporal Resolution Dynamic Contrast-Enhanced MR Enterography in Crohn Disease Terminal Ileitis Using Continuous Golden-Angle Radial Sampling, Compressed Sensing, and Parallel Imaging. AJR Am J Roentgenol 2015;204:W663-9. [PMID: 26001254 DOI: 10.2214/AJR.14.13674] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
5 Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J. Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody. J Intern Med 2016;279:41-59. [DOI: 10.1111/joim.12432] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
6 Marquez-Megias S, Ramon-Lopez A, Más-Serrano P, Diaz-Gonzalez M, Candela-Boix MR, Nalda-Molina R. Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. Pharmaceutics 2021;13:1244. [PMID: 34452204 DOI: 10.3390/pharmaceutics13081244] [Reference Citation Analysis]
7 Moon W. Golimumab Therapy in Ulcerative Colitis. Korean J Gastroenterol 2016;67:64. [DOI: 10.4166/kjg.2016.67.2.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Wei P, Yang Y, Ding Q, Li X, Sun H, Liu Z, Huang J, Gong Y. Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis. J Med Microbiol 2016;65:160-8. [PMID: 26567174 DOI: 10.1099/jmm.0.000197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
9 Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016;68:282-298. [PMID: 26401991 DOI: 10.1002/art.39298] [Cited by in Crossref: 254] [Cited by in F6Publishing: 197] [Article Influence: 36.3] [Reference Citation Analysis]
10 Zhang F, Zhang Y, Wang K, Zhu X, Lin G, Zhao Z, Li S, Cai J, Cao J. Diallyl trisulfide inhibits naphthalene-induced oxidative injury and the production of inflammatory responses in A549 cells and mice. International Immunopharmacology 2015;29:326-33. [DOI: 10.1016/j.intimp.2015.10.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
11 Chou JW, Lai HC, Chang CH, Cheng KS, Feng CL, Chen TW. Epidemiology and Clinical Outcomes of Inflammatory Bowel Disease: A Hospital-Based Study in Central Taiwan. Gastroenterol Res Pract. 2019;2019:4175923. [PMID: 31312216 DOI: 10.1155/2019/4175923] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
12 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3. [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038] [Cited by in Crossref: 274] [Cited by in F6Publishing: 249] [Article Influence: 34.3] [Reference Citation Analysis]
13 Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A. Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis. J Crohns Colitis. 2016;10:575-581. [PMID: 26738756 DOI: 10.1093/ecco-jcc/jjv241] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
14 Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015;27:118-26. [PMID: 25603040 DOI: 10.1097/BOR.0000000000000152] [Cited by in Crossref: 105] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
15 Vadstrup K, Galsgaard ED, Gerwien J, Vester-Andersen MK, Pedersen JS, Rasmussen J, Neermark S, Kiszka-Kanowitz M, Jensen T, Bendtsen F. Validation and Optimization of an Ex Vivo Assay of Intestinal Mucosal Biopsies in Crohn's Disease: Reflects Inflammation and Drug Effects. PLoS One 2016;11:e0155335. [PMID: 27171179 DOI: 10.1371/journal.pone.0155335] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
16 Dubé PE, Liu CY, Girish N, Washington MK, Polk DB. Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice. Sci Rep 2018;8:9119. [PMID: 29904166 DOI: 10.1038/s41598-018-27353-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Gisbert JP, Domènech E. Vedolizumab en el tratamiento de la enfermedad de Crohn. Gastroenterología y Hepatología 2015;38:338-48. [DOI: 10.1016/j.gastrohep.2014.12.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ferreira SDC, Nóbrega FJF, de Araújo RC, de Almeida PH, Villanova MG, Santana RC, Zambelli Ramalho LN, Martinelli ALC, Troncon LEA. Histoplasmosis Related to Immunosuppression in a Patient with Crohn's Disease: A Diagnostic Challenge. Am J Case Rep 2021;22:e925345. [PMID: 34495947 DOI: 10.12659/AJCR.925345] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yu Y, Song EM, Lee KE, Joo YH, Kim SE, Moon CM, Kim HY, Jung SA, Jo I. Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis. PLoS One 2017;12:e0183141. [PMID: 28854223 DOI: 10.1371/journal.pone.0183141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
20 Kolios G. Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None? Dig Dis Sci 2016;61:330-1. [PMID: 26694171 DOI: 10.1007/s10620-015-3997-x] [Reference Citation Analysis]
21 Dziechciarz P, Horvath A, Kierkuś J. Efficacy and Safety of Adalimumab for Paediatric Crohn's Disease: A Systematic Review. J Crohns Colitis 2016;10:1237-44. [PMID: 26995184 DOI: 10.1093/ecco-jcc/jjw077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
22 Gómez-Gómez GJ, Masedo &, Yela C, Martínez-Montiel MDP, Casís B. Current stage in inflammatory bowel disease: What is next? World J Gastroenterol 2015; 21(40): 11282-11303 [PMID: 26525013 DOI: 10.3748/wjg.v21.i40.11282] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
23 Kadivar M, Petersson J, Svensson L, Marsal J. CD8αβ+ γδ T Cells: A Novel T Cell Subset with a Potential Role in Inflammatory Bowel Disease. J Immunol 2016;197:4584-92. [PMID: 27849165 DOI: 10.4049/jimmunol.1601146] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
24 Lynch KD, Keshav S, Chapman RW. The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Curr Hepatol Rep. 2019;18:115-126. [PMID: 31008013 DOI: 10.1007/s11901-019-00456-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Husni ME. Comorbidities in Psoriatic Arthritis. Rheum Dis Clin North Am 2015;41:677-98. [PMID: 26476226 DOI: 10.1016/j.rdc.2015.07.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 54] [Article Influence: 11.1] [Reference Citation Analysis]
26 Vadstrup K, Bendtsen F. Anti-NKG2D mAb: A New Treatment for Crohn's Disease? Int J Mol Sci 2017;18:E1997. [PMID: 28926962 DOI: 10.3390/ijms18091997] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
27 Wang Y, Zhang J, Gao X, Li Q, Sun D. In vitro and in vivo anti-inflammatory effect of Zaluzanin D isolated from Achillea acuminate. Int Immunopharmacol 2021;90:107130. [PMID: 33218937 DOI: 10.1016/j.intimp.2020.107130] [Reference Citation Analysis]
28 Kim B, Chae J, Kim EH, Yang HI, Cheon JH, Kim TI, Kim WH, Jeon JY, Park SJ. Physical activity and quality of life of patients with inflammatory bowel disease. Medicine (Baltimore) 2021;100:e26290. [PMID: 34232167 DOI: 10.1097/MD.0000000000026290] [Reference Citation Analysis]
29 Leung G, Papademetriou M, Chang S, Arena F, Katz S. Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. Curr Treat Options Gastro 2016;14:507-34. [DOI: 10.1007/s11938-016-0109-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol 2014;4:209. [PMID: 26539323 DOI: 10.4172/2161-0495.1000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Krauss AH, Corrales RM, Pelegrino FS, Tukler-Henriksson J, Pflugfelder SC, de Paiva CS. Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model. Invest Ophthalmol Vis Sci 2015;56:5888-95. [PMID: 26348638 DOI: 10.1167/iovs.15-17249] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
32 Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, Van Den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 2016;68:151-66. [PMID: 26401907 DOI: 10.1002/acr.22708] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]